VIDEO: Amy’s XV LVAS story
By popular demand at today’s Extraordinary General Meeting, how patient Amy’s post-COVID condition was revealed by XV Technology. [Duration 2:23]
EVENT: 4DMedical at ATS 2023 [Day 3]
4DMedical is sustaining its longstanding relationship with the American Thoracic Society and is a prominent program participant and exhibitor at the ATS 2023 annual conference 19-24 May; the world’s largest gathering for the pulmonary sciences professions. Day 3 video digest [Duration 1:19]
EVENT: 4DMedical at ATS 2023 [Day 2]
4DMedical is sustaining its longstanding relationship with the American Thoracic Society and is a prominent program participant and exhibitor at the ATS 2023 annual conference 19-24 May; the world’s largest gathering for the pulmonary sciences professions. Day 2 video digest [Duration 1:04]
NEWS: 4DMedical unveils VQ product at premier U.S. lung conference
CT:VQ technology announced at ATS 2023. Read the ASX Announcement.
EVENT: 4DMedical at ATS 2023 [Day 1]
4DMedical is sustaining its longstanding relationship with the American Thoracic Society and is a prominent program participant and exhibitor at the ATS 2023 annual conference 19-24 May; the world’s largest gathering for the pulmonary sciences professions. Day 1 video digest [Duration 1:11]
NEWS: Dr Andreas Fouras Truman VA ATO interview on #ausbiz
Danielle Ecuyer talks with 4DMedical MD/CEO Dr Andreas Fouras on granting of an Authority to Operate (ATO) by the U.S. Veterans Health Administration representing achievement of a significant milestone, recognising the robustness and security of 4DMedical’s XV Technology integrated with VA information networks — on...
NEWS: MD/CEO Dr Andreas Fouras interview on #ausbiz
Nadine Blayney talks with 4DMedical MD/CEO Dr Andreas Fouras on the success of the company’s $20 million capital raise, forthcoming SPP and future strategic direction — on #ausbiz. Screened Tuesday 9 May 2023; duration 06:01
EVENT: Capital Raising Presentation 9 May 2023
Capital Raising Presentation webinar to shareholders by MD/CEO Dr Andreas Fouras; Tuesday 9 May 1100AEST Access the recording here.
NEWS: Dr David Shulkin, MD, joins 4DMedical in key advisory role.
4DMedical today announces the appointment of former U.S. Secretary for Veterans Affairs and accomplished health care systems leader Dr David Shulkin, MD to an advisory role within the Company:
NEWS: 4DMedical signs first U.S. hospital SaaS contract
Five–year contract agreed to deliver XV LVAS® scans to the University of Miami, effective immediately Click here to access ASX Announcement
NEWS: Governor of Victoria Linda Dessau briefed on XV Technology and 4DMedical future
Dr Andreas Fouras joined luminaries including University of Melbourne Vice Chancellor Professor Duncan Maskell and the Doherty Institute’s Professor Sharon Lewin as the only medical technology company participating in a special briefing for Governor of Victoria, HE Linda Dessau during a visit to Melbourne Connect...
NEWS: 4DMedical celebrates IWD2023
On International Women’s Day 8 March (IWD2023) , our 4DMedical team came together to reflect upon the contribution of women to the engineering and medical sciences, and to celebrate the role of women in our company’s many achievements. In her address to staff and guests...
UPDATE: Quarterly Activity Report / 4C for Q2 FY2023; customer receipts up 396%
Latest Quarterly Activity Report and Appendix 4C released by 4DMedical today reveals patient access to XV Technology® expanded to 27 I-MED sites. strong cash balance of $45.7 million, and receipts from customers of $0.7m for the quarter, up 396% — amongst many highlights. Learn more...
NEWS: Professor Bruce Thompson recognised in Australia Day honours
Professor Bruce Thompson, a member of 4DMedical’s expert Advisory Board, has been recognised in the 2023 Australia Day Honours list. Currently Head of the Melbourne School of Health Sciences at 4DMedical’s primary academic and research partner, the University of Melbourne, Professor Thompson’s distinguished career includes...
NEWS: “My scan today is a major step forward for fellow veterans who are suffering from burn pit exposures and are desperate for answers,” — Captain Le Roy Torres, U.S. Army
MIAMI, Jan. 12, 2023 — 4DMedical, the leading developer of functional imaging software for respiratory illness, announced that Army Captain Le Roy Torres received a four-dimensional scan using 4D’s XV LVAS technology today at the University of Miami Leonard M. Miller School of Medicine. 4DMedical’s...
NEWS: 4DMedical Debuts “XV Scanner,” Most Advanced Lung Scanning Technology in Decades At RSNA
4DMedical will unveil the “XV Scanner,” a breakthrough lung scanning device that integrates fluoroscopy with advanced analytics software at the 2022 annual meeting of the Radiological Society of North America (RSNA) in Chicago. “In the history of scanning technology, there have been very few fundamentally...
EVENT: 4DMedical at Emerging ASX Gems conference 11NOV2022
MD/CEO Dr Andreas Fouras presents at The Capital Network’s online Emerging ASX Gems conference 11NOV2022, on the topic of how 4DMedical is delivering shareholder value. Register for free via Eventbrite.
NEWS / MEDIA: Dr Jason Kirkness honoured as Top 25 Healthcare Technology Leader
4DMedical’s Senior Vice President Medical and Clinical Affairs has been recognised for his contribution to the emergence of Los Angeles as a hub for healthcare innovation. Dr Jason Kirkness is one of 25 honoured by the Healthcare Technology Report today. The Top 25 Healthcare Technology...
ASX ANNOUNCEMENT: 4DMedical releases CT LVAS™ in Australia
4DMedical today announces the release of its breakthrough image processing software, CT LVAS™, providing an almost identical report to 4DMedical’s proven XV LVAS® product but utilising widely available Computed Tomography (CT) imaging infrastructure in providingclinicians and patients with the benefits of XV Technology®.
ASX ANNOUNCEMENT: AMA granting CPT code represents significant commercialisation step for XV LVAS in U.S. market
The American Medical Association (AMA) has accepted 4DMedical’s application for a new Category III CPT code identifying use of XV Lung Ventilation Analysis Software (‘XV LVAS®’) technology. Acquiring this distinct code is a critical step towards commercial success in the U.S. allowing healthcare providers to...
EVENT: 4DMedical at RSNA 2022 in Chicago 27-30 November
4DMedical is exhibiting at the annual conference of the Radiological Society of North America. RSNA 2022: 27-30 November in Chicago
NEWS: Rep. Mikie Sherrill (D-NJ) discusses PACT Act implementation with Dr Andreas Fouras and Rosie Torres
4DMedical CEO Dr Andreas Fouras and U.S. veterans advocate Rosie Torres of Burn Pits 360 met earlier today with Congresswoman and Navy veteran Mikie Sherrill, discussing implementation of the PACT Act and the capability of XV Technology to enable effective diagnoses and care for America’s...
NEWS: 4DMedical formalises relationship with the University of Melbourne
The longstanding relationship between 4DMedcial and its primary research and academic partner, the University of Melbourne, has been formalised through signing of a Memorandum of Understanding (MoU). The two organisations collaborate in a number of spheres that will widen to include use of XV Technology...
MEDIA: FY2021-22 Full year results; Dr Andreas Fouras on ausbiz tv
MD/CEO Dr Andreas Fouras talks revenue growth, clinical trials validating technological application and commercial piloting expansion successes during FY2021-22 in interview with Nadine Blayney on ausbiz 19 AUG 2022.
LETTER from the CEO following the passage of the PACT Act by the U.S. Congress
At 4DMedical we are acutely aware of the debt owed to so many United States serving and former military personnel. The passing of the Sergeant First Class Heath Robinson Honoring Our PACT Act of 2022 (“PACT Act”) this week by Congress recognises the tragic legacy...
MEDIA RELEASE: 4DMedical Praises Senate Passage of PACT Act
We commend Congress for passing this critical legislation. The PACT Act ensures veterans exposed to toxic substances and airborne hazards during service will have access to healthcare technologies and disability benefits specific to their conditions.
MEDIA RELEASE: Burn Pit Population Surveillance in FY 2023 U.S. Appropriations
VA to evaluate “emerging technology using existing x-ray imaging equipment to derive four-dimensional models of lung function.” Four-dimensional scanning software is one of those “emerging technologies” available right now to help veterans suffering from respiratory illness.
MEDIA: 4DMedical COPD trial results presented at US lung conference
Announcement of Johns Hopkins clinical trial results and presentation at ATS 2022 reported in BiotechDespatch.
EVENT: 4DMedical at ATS 2022 in San Francisco 15-18 May
The American Thoracic Society (ATS) annually stages the world’s largest gathering of respiratory health professionals. ATS 2022 is being held 15-18 May in San Francisco, with 4DMedical prominent in the program, scientific paper presentations and in the exhibit hall. Follow our social media to stay...
MEDIA RELEASE: Hilary Byrne joins 4DMedical as REDI Fellow
University of Sydney researcher Dr Hilary Byrne has been funded by MTPConnect to join 4DMedical on a REDI Fellowship:
EVENT: A 48 hour sprint to reimagine the future of healthcare
4DMedical is proud to be principal sponsor of MYMI Medhack Elevate. The intellect of today guiding the imagination of tomorrow. mymi.org.au/medhack
MEDIA: The pandemic has put diagnostic respiratory health on the radar of major players
MD/CEO Dr Andreas Fouras in today’s Sydney Morning Herald: “If you are in respiratory and there is a real opportunity to be part of the solution for COVID, there is a really significant value opportunity right now.”
First commissioned XV Scanner unveiled to Minister Greg Hunt in Sydney
A significant milestone for 4DMedical’s journey as a company and the evolution of medical imaging has been realised. Minister for Health Greg Hunt MP was a special guest at the unveiling of the world’s first dedicated lung scanner, the Generation One XV Scanner, at Prince...
SOCIAL MEDIA ALERT: U.S. Secretary of State visits 4DMedical global headquarters
Anthony Blinken, U.S. Secretary of State briefed on the capabilities of XV Technology and particularly its application to America’s veterans and military personnel impacted by Postdeployment Respiratory Syndrome. FURTHER UPDATE 1524AEDT today with Secretary Blinken Twitter. UPDATE via Twitter. Imagery to follow.
MEDIA RELEASE: Commercial rollout of four-dimensional respiratory scanning expands into three new markets
General practitioners and respiratory specialists in Brisbane, Wagga Wagga and Albury can now order highly visual reports of patients’ lung function based upon four-dimensional scans, as 4DMedical’s collaboration with I-MED Radiology Network expands into new markets.
SOCIAL MEDIA ALERT: Electromagnetic compatibility testing for scanner
MD/CEO Dr Andreas Fouras on EMC testing in Melbourne today [LinkedIn]: “Our progress against an ambitious strategy to translate research and improve respiratory health through technology is relentless.”
SOCIAL MEDIA ALERT: World’s first dedicated lung scanner becoming a reality
MD/CEO Dr Andreas Fouras progress update on LinkedIn
MEDIA RELEASE: 4DMedical teaming with Alfred Health to apply four-dimensional imaging in lung transplant patient assessment
Application of 4DMedical’s XV Technology to assessing candidates for lung transplant is being validated during Greg Snell-led FIT Study currently underway in Melbourne
LATEST NEWS: First commercial rollout of four-dimensional respiratory scanning to commence December
General practitioners and respiratory specialists in south-eastern Melbourne will soon be able to order highly visual reports of patients’ lung function based upon four-dimensional scans, following successful completion of pilot programs by 4DMedical in collaboration with I-MED Radiology Network, Australia’s largest diagnostic imaging provider. Commencing...
LATEST NEWS: 4DMedical and Kailo Medical partnering to connect healthcare networks with XV Technology cloud processing
Australia-wide access to 4DMedical’s cloud-based XV Technology, enabling unprecedented understanding of lung motion and airflow, is moving closer to reality through a partnership announced today with leading integration provider, Kailo Medical. 4DMedical’s XV Technology Lung Ventilation Analysis Software (XV LVAS) provides highly detailed maps of...
CLINICAL TRIAL UPDATE: Application of XV Technology to lung transplant added to clinical trials program
Lung transplants offer people afflicted with incurable respiratory disease the prospect of a better quality of life – XV Technology optimises success of expensive, resource-intensive procedures. Alfred Health-based ‘FIT’ Study announced today involves 40 patients affected by conditions including interstitial lung disease, severe COPD, pulmonary...
CLINICAL TRIAL UPDATE: First imaging at Johns Hopkins
Clinical trials are a core pillar of 4DMedical’s commercialisation strategy. The iconic Johns Hopkins Medical Center exemplifies the quality of our partners evolving scientific investigation into case application. Achieving ‘first imaging’ status in Baltimore represents further progress against strategy. See the status of our clinical...
CLINICAL TRIAL UPDATE: First imaging at Cleveland Clinic
4DMedical’s intensive clinical trials program continues to progress against strategy with the announcement of our Cleveland Clinic-based activity reaching ‘first imaging’ status, despite the ongoing COVID-19 challenge. Our commitment to this ongoing program of clinical trials grows a body of scientific evidence driving market uptake....
LATEST NEWS: 4DMedical one of “Three Emerging Medical Device Companies” profiled by Switzer/NABtrade
James Dunn commentary: “Imaging company 4DMedical (4DX) surged on to the ASX screens in its August 2020 float, with the shares, issued in the prospectus at 73 cents, opening for trade at $1.47. 4DX reached $2.60 in October 2020, but more than halved subsequently, plumbing...
XV Technology’s application to monitoring the post-COVID condition shown on U.S. network news channels
VIDEO: XV Technology’s application to monitoring the post-COVID condition shown on Fox, NBC, CBS and ABC network news channels across America. “Doctors in California are using four-dimensional lung scans…” Vision from Fox32 Chicago:
LATEST NEWS: World’s first four dimensional post-COVID lung imagery provides new insight into long-term effects of disease
The world’s first four-dimensional visual insight into the residual effects of COVID-19 or ‘long COVID’ providing an unprecedented ability for patients, clinicians and researchers to understand the ongoing impact of this disease has been obtained using 4DMedical’s unique XV Technology. 4DMedical today confirmed that COVID-afflicted...
VIDEO: Ticker TV interviews CEO Andreas Fouras on commercial evaluation with I-MED Radiology Network
LATEST NEWS: 4DMedical announces Phase Two of Australian clinical pilot program with I-MED Radiology Network
Medtech innovator 4DMedical announces Phase Two of Australian clinical pilot program with I-MED Radiology Network Following successful completion of a comprehensive clinical pilot program conducted in collaboration with I-MED Radiology, Australia’s largest diagnostic imaging network, 4DMedical announces plans for a Phase Two program commencing immediately....
LATEST NEWS: 4DMedical partners with Asthma Australia assisting 2.7 million people to breathe easier
4DMedical partners with Asthma Australia assisting 2.7 million people to breathe easier Today, Asthma Australia and 4DMedical announce a partnership recognising a mutual commitment to promote awareness and improve diagnostic technology for 2.7 million people living with asthma. Asthma is a life-long respiratory condition which,...
MEDIA RELEASE: 4DMedical partnering with Lung Foundation Australia
MEDIA RELEASE 19 August 2021 4DMedical partnering with Lung Foundation Australia to prepare for a post-COVID nation Medical imaging innovator 4DMedical is teaming with Lung Foundation Australia to protect the health and wellbeing of people impacted by the residual physiological effects of the COVID-19 pandemic....
Dr Jason Kirkness co-author of Johns Hopkins study published in ‘European Respiratory Journal’
JOURNAL ARTICLE ‘Obesity, tidal volume, and pulmonary deposition of fine particulate matter in children with asthma’: 4DMedical’s Vice President Medical and Clinical Affairs, Dr Jason Kirkness is co-author of a Johns Hopkins University-led study published in the European Respiratory Journal [Eur Respir J]. Read the...
MEDIA RELEASE: 4DMedical signs commercial contract with pharmaceutical company
MEDIA RELEASE 9 August 2021 4DMedical signs commercial contract with pharmaceutical company Respiratory imaging disruptor 4DMedical (ASX:4DX) today announced the signing of a commercial contract with Novartis. Under the terms of the agreement, XV Ventilation Reports will be provided to Novartis on a commercial basis....
MEDIA RELEASE: 4DMedical launches comprehensive clinical program for interventional pulmonary treatments
MEDIA RELEASE 5 August 2021 Respiratory imaging disruptor 4DMedical announces further application of its XV LVAS (Lung Ventilation Analysis Software) technology, through its use in validating interventional pulmonary treatments in a range of clinical activities in the United States. The interventional pulmonology market valued at...
Portfolio manager Andrew Mouchacca on 4DMedical success and potential: Australian Financial Review’s Techinvest magazine
Flinders Investment Partners on ‘Groundbreaking technology, market opportunity and compelling partnerships’: Australian Financial Review‘s latest Techninvest edition:
CEO/MD Dr Andreas Fouras personal insights into clinical trials with the iconic Johns Hopkins Medical Center
Further validation of XV Technology application to COPD conditions, with results communicated to the global clinical and medical research communities by respected Johns Hopkins experts.
PPAHS recognises need for improved technologies for measuring lung dynamics and function during pandemics.
US advocacy organisation, the Physician-Patient Alliance for Health & Safety (PPAHS) has published a Position Paper recognising the need for improved technologies and procedures to measure lung dynamics and function during pandemics.
4DMedical commences COPD-focused clinical trial with Johns Hopkins School of Medicine
A second clinical trial validating the clinical application of 4DMedical’s XV Technology has commenced at Johns Hopkins University in Baltimore, one the world’s most renowned centres of research translation. Read more about our comprehensive program of clinical trials.
VALE Jeffrey R. Goldstein
The 4DMedical community reflects upon the life and achievements of Jeff Goldstein, President and Founding Member, Lung Transplant Foundation, and a respected and valued partner in seeking to improve the lives of those afflicted with lung diseases. Jeff fulfilled both executive and board responsibilities within...
NIH funds US$600k commercial sale of Permetium scanner to University of Michigan
The influential and respected U.S. National Institutes of Health (NIH) has validated the multiple capabilities of 4DMedical’s Permetium pre-clinical scanner, enabling a $600,000 commercial purchase by the University of Michigan. In a comprehensive funding submission to the NIH, Michigan recognised Permetium as “the only commercially available...
4DMedical partners with U.S. Respiratory Compromise Institute (RCI) for clinical pilot program
4DMedical is pleased to announce it has partnered with the Respiratory Compromise Institute to implement 4DMedical’s XV Lung Ventilation Analysis Software (XV LVAS™) at eight clinical sites located across the U.S.
April Newsletter featuring $28.9m MRFF grant funding success for XVD scanner
MRFF grant funding success and a 7 News network television appearance by MD/CEO Dr Andreas Fouras feature in this edition.
Dr Andreas Fouras and XVD technology potential on 7 News
Dr Andreas Fouras and the ALHI Generation One scanner in a 7 News exclusive feature broadcast nationally to 1.64 million viewers on Friday 19 March. Dr Fouras explains the potential of the XVD scanner being developed through Medical Research Future Fund support to the Australian...
Newsletter – December 2020
4DMedical Announcements in the December 2020 Newsletter! Please click on the image below to read and/or download the newsletter.
Announcement: 4DMedical & the University of Miami announce the creation of the Functional Lung Imaging Research Program
UHealth – the University of Miami Health System, the University of Miami Miller School of Medicine, and 4DMedical recently announced the creation of the Functional Lung Imaging Research Program in the Department of Medicine’s Division of Pulmonary, Critical Care and Sleep Medicine at the Miller...
ATS Research Program, 4DMedical Announce Grant Opportunities for Research in Asthma, COPD and IPF
Oct. 01, 2020 – Today, the ATS Research Program announced three research grant opportunities with support from 4DMedical, a global medical technology company with a focus on lung health. With a total grant support of $150,000, each of the three $50,000 grants will fund research...
Australian Financial Times: 4DMedical float set to sizzle, as funds pile in
Aug 6, 2020 – 4.17pm by Yolanda Redrup In the eight years since former Monash University professor Andreas Fouras founded soon-to-be listed lung imaging medical technology company 4D Medical, he has put everything on the line to get his business to where it is...
Going from uni lab to hospital theatre demands huge sacrifice
Andreas Fouras imagined he would always be a university professor. The research milieu suited him and he made the transition from graduate to professor in biomechanical engineering in a remarkably short six years. Now he has logged seven years running a biomedical company and his...
Lung tracker gears up for ASX launch
Home grown lung tracker biotech 4DMedical has confirmed it expects to hit the ASX boards on August 14th after it completes a $50 million IPO with shares on offer at 73c each. The company’s XV Technology platforms helps doctors track respiratory illnesses with more accuracy...
Another medtech stock is about to hit the ASX block…and it’s already been FDA cleared
In a few weeks time respiratory diagnostic company 4DMedical will list on the ASX. The company’s technology, XV, helps physicians monitor lung performance and identify disorders utilising less radiation and no dyes at all. 4DMedical has launched a $50m IPO and is expected to list...
The City Beat
BREATHING EASIER Brisbane-born entrepreneur Andreas Fouras (illustrated) is poised to radically shake up how doctors around the world diagnose and treat lung ailments. His start-up company 4DMedical announced a $50m IPO on Friday to drive the growth of groundbreaking technology he developed and which he...
4DMedical kicks off $189m IPO two weeks early
Sarah Thompson, Anthony Macdonald and Tim Boyd Jun 29, 2020 – 11:03am When the excitement of bookbuild day comes around, it pays to stay calm and breathe easy. 4DMedical founder Andreas Fouras. Wayne Taylor And in the case of ASX aspirant and lung imaging technology outfit 4DMedical – which is raising...
US FDA clears 4DMedical’s new respiratory diagnostic tool, XV Technology
Woodland Hills, California Tuesday, May 26, 2020, 10:00 Hrs [IST] Australian medical technology company, 4DMedical has received clearance from the US Food & Drug Administration to market its XV Technology, a patented four-dimensional lung imaging process that rapidly and automatically analyses any functional lung impairment...
FDA clears 4D Medical’s lung imaging technology
MAY 26, 2020 BY SEAN WHOOLEY 4DMedical announced that it received FDA clearance for its XV Technology for analyzing functional lung impairment from a single X-ray. Australia-based 4DMedical (formerly 4DX), which has a U.S. base in Woodland Hills, Calif., designed the XV Technology as a four-dimensional lung imaging...
Verdict Medical Devices: US FDA clears 4DMedical’s lung imaging technology
26 MAY 2020 4DMedical’s XV Technology automatically analyses any functional lung impairment from a single X-ray. Credit: Stillwaterising / Wiki Commons. The US Food and Drug Administration (FDA) has granted regulatory clearance to 4DMedical to market its four-dimensional lung imaging process XV Technology. The technology...
Asian Hospital & Healthcare Management: 4DMedical’s Lung Imaging Technology Receives FDA Clearance as COVID-19 Intensifies Global Focus on Respiratory Health
TUESDAY, MAY 26, 2020 4DMedical, an Australian medical technology company specializing in medical imaging innovation software, announced today it has received clearance from the U.S. Food & Drug Administration to market its XV Technology™, a patented four-dimensional lung imaging process that rapidly and automatically analyses...
MJH Life Sciences, Diagnostic Imaging: FDA Awards Clearance to 4D Lung Imaging Software
Written by: Whitney J. Palmer 4DMedical, an Australian-based medical innovation software company, announced Tuesday it has received 510(k) clearance from the U.S. Food & Drug Administration for its XV Technology™, a four-dimensional lung imaging process. According to a company statement, XV Technology™ can quickly...
Smart Market News: 4DMedical’s Lung Imaging Technology Receives FDA Clearance as COVID-19 Intensifies Global Focus on Respiratory Health
“Our XV Technology™ is a valuable new respiratory diagnostic tool,” said 4DMedical founder and CEO, Andreas Fouras, Ph.D. “It provides critical information about the functional and structural state of a patient’s lungs in the treatment of illnesses such as COVID-19, asthma, chronic obstructive pulmonary disease, cystic...
BiotechDispatch: US clearance for 4DMedical’s lung imaging product
Australian medical technology company 4DMedical (formerly known as 4Dx) says it has received clearance from the FDA to market its four-dimensional XV Technology lung imaging product – XV Lung Ventilation Analysis Software. 4DMedical Founder and CEO Dr Andreas Fouras said, “XV Technology is a valuable respiratory diagnostic...
Cision PR News: 4DMedical’s Lung Imaging Technology Receives FDA Clearance as COVID-19 Intensifies Global Focus on Respiratory Health
May 25, 2020 WOODLAND HILLS, Calif., May 25, 2020 /PRNewswire/ — 4DMedical, an Australian medical technology company specializing in medical imaging innovation software, announced today it has received clearance from the U.S. Food & Drug Administration to market its XV Technology™, a patented four-dimensional lung imaging process that...
Guided Solutions.co.uk: 4DMedical gets FDA clearance for new respiratory diagnostic tool
Posted: May 25, 2020 Australian medical technology company 4DMedical has secured clearance from the US Food & Drug Administration for its lung imaging technology. The regulator has cleared XV Technology, which is a patented four-dimensional lung imaging process that quickly and automatically analyses any functional...
BioSpace.com: 4DMedical’s Lung Imaging Technology Receives FDA Clearance as COVID-19 Intensifies Global Focus on Respiratory Health
Published: May 25, 2020 WOODLAND HILLS, Calif., May 25, 2020 /PRNewswire/ — 4DMedical, an Australian medical technology company specializing in medical imaging innovation software, announced today it has received clearance from the U.S. Food & Drug Administration to market its XV Technology™, a patented four-dimensional lung imaging process that rapidly...
Lung tracker considers ASX tilt
As printed in the The Age Friday 22nd May 2020 Page 27 | Section: BUSINESS ASX medtech hopeful 4D Medical has joined a pack of Australian start-ups hoping to get a green light from the US Food and Drug Administration (FDA) to market its...
Biotech Daily – May 21
4D MEDICAL (FORMERLY 4DX) Melbourne’s 4D says the US Food and Drug Administration has cleared its “four-dimensional” XV lung ventilation analysis software imaging product for sale in the US. 4D said that the XV technology was not intended to replace primary diagnostic tests, such as...
Australian Financial Review: 4D Medical gets nod from FDA, pushes ahead with float plans
Written by Carrie LaFrenz, Senior Reporter May 21, 2020 – 12.30am Medical-technology developer 4D Medical is pushing ahead with its ASX float plans despite the market turmoil after getting the nod from the powerful US Food and Drug Administration to market its lung-imaging product. The...
Invention Breathes New Life Into Treatment
As printed in The Daily Telegraph, Thursday 30th April 2020 By Charles Miranda A TEAM of Australian scientists has created a groundbreaking “field ventilator” to help combat coronavirus in remote regions of Australia and overseas where hospital emergency resources are limited. And critically they are...
Field Ventilator to Combat Corona
As printed in The Courier Mail, Thursday 30th April 2020 By Charles Miranda A TEAM of Australian scientists has created a groundbreaking “field ventilator” to help combat coronavirus in remote regions where hospital emergency resources are limited. And critically they are going into production in...
Device to Help Win Virus War
Ventilator Boost for Regions As printed in The Advertiser, Thursday 30th April 2020 By Charles Miranda ADELAIDE scientists have helped create a groundbreaking “field ventilator” to combat coronavirus in remote regions across Australia and overseas. And the device will go into production in Australia,...
Aussie Ventilator a Grey Area
As printed in The Herald Sun Friday, 1st May 2020 By Miranda Devine & Charles Miranda A VICTORIAN biotech company awarded a $31 million federal contract to build Australian-made ventilators for coronavirus patients has admitted multiple components will be sourced overseas, including from China. And...
Lung imaging software may fast-track coronavirus diagnosis
4DX chief executive and founder Andreas Fouras. Picture: Roy VanDerVegt Posted on The Australian, 11 March 2020 An Australian medical technology company is hoping to forge the pathway to a fast-tracked coronavirus diagnosis by reducing the diagnostic time to three hours. 4DX is seeking...
IPO Preparation Update
4Dx has appointed E&P (formerly Evans and Partners) and Bell Potter Securities as joint lead managers of its proposed IPO.
Non-invasive XV Technology May Lead to Faster CF Diagnosis and Better Treatment
As posted in Cystic Fibrosis News Today, February 2020 By MARGARIDA AZEVEDO, MSC A new non-invasive tool, called XV Technology™, allows professionals to visualize airflow in a living lungs and could help in the diagnosis, monitoring, and treatment of cystic fibrosis (CF) and other respiratory lung diseases, scientists report.™...
4Dx article – Mirage News
4Dx in the news! Check out the latest article on our technology on the Mirage News website: https://www.miragenews.com/second-wind-new-technology-to-help-diagnose-and-manage-respiratory-diseases/
4Dx Hiring
4Dx is continuing to grow! Two new job postings for the Melbourne office were posted today on our Careers page: https://4dx.com/careers
FDA Acceptance Review Notification – 4Dx 510(k) Accepted
The US Food and Drug Administration (FDA) conducted its administrative acceptance review on 4Dx’s premarket notification (510(k)), and found it contained all of the necessary elements and information needed to proceed with the substantive review.
4Dx $15 million Pre-IPO News Hits News Outlets
New news releases from BioMelbourne Network and Biotech Daily, Dec. 10, 2019: (https://biotechdispatch.com.au/news/4dx-raises-15m-in-oversubscribed-capital-raise) ****************** 10 December 2019 Melbourne, Australia: Australian medical technology company 4Dx Limited has raised $15 million in a heavily oversubscribed pre-IPO. The funds raised via the unsecured converting note issue will...
4Dx Completes FDA Submission Documentation
FOR IMMEDIATE RELEASE As of November 10, 2019, 4Dx is proud to announce that all documents required to support an FDA 510(k) application have been handed over to its agent for electronic submission. After a tremendously successful clinical validation trial, 4Dx founder and CEO, Andreas...
Dr. Sam Hupert, CEO of Pro Medicus, Joins 4Dx Advisory Board
4Dx is pleased to announce the appointment of Dr. Sam Hupert, co-Founder and CEO of Pro Medicus (ASX: PME) to the 4Dx advisory board. Dr. Hupert has made a private investment into 4Dx and agreed to sit on 4Dx’s advisory board, bringing with him more than...
Biotech Daily – “4DX: ‘XV BEATS PFT, CT FOR LUNG HEALTH’”
From Biotech Daily – released Friday, November 1, 2019 4DX LIMITED 4DX says a 32-patient, 13-month study shows that its XV technology is superior to “gold standard pulmonary diagnostics” to measure lung health. 4DX said the study, titled ‘Novel x-ray velocimetry based quantitative regional...
New 4Dx article on Stockhead website
A new article was posted today on Stockhead.com, an online health & technology news service focusing on big discoveries, medical breakthroughs and revolutionary technologies.
4Dx Presents First Human Scan Data From XV Technology Clinical Trials
Andreas Fouras, PhD, (founder and CEO of 4Dx) presented this week the first release of the highly anticipated results from 4Dx’s clinical trials at the American Thoracic Society (ATS) 2019 International Conference in Dallas, TX, 4Dx opened Day 1 of the 3-day conference with a...
FUNDING FOR GROUND-BREAKING LUNG DIAGNOSTIC TECHNOLOGY
The Hon. Greg Hunt MP Minister for Health MEDIA RELEASE FUNDING FOR GROUND-BREAKING LUNG DIAGNOSTIC TECHNOLOGY The Liberal National Government will provide $960,000 for intensive research into new 4D diagnostic technology to allow accurate assessment of lung function in patients of all ages including the...
Wind Tunnel Technology Fights Lung Disease
Headquartered in Westlake Village, CA, 4DX developed a medical technology that has the capacity to simply, safely, and effectively view lung air flow function in fine detail. Andreas Fouras, CEO of 4DX, and a mechanical engineer by training, is behind this innovation. While working...
Radiology Today Magazine: More With Less
Advanced software reduces dose without sacrificing image quality. Although the direct health risk of medical diagnostic scanning is not unequivocally clear, it is important for patients as well as health care professionals to mitigate the risks of radiation dose. While most of the concern...
MD+DI Online Interview: An Australian Startup’s Unique Approach to Imaging Lung Function
4Dx has developed an algorithm-based software that converts X-ray images into more detailed airflow studies. 4Dx is developing a software-as-a-service technology that enables four-dimensional lung imaging tests using the imaging equipment already in place at hospitals and other clinical settings. The company expects to have...
Medical imaging startup takes new approach to viewing lung disease
The company’s algorithms use existing fluoroscopy technology, which captures structures in motion and is commonly used to image the cardiovascular system or direct invasive procedures. Lung diseases, like asthma, cystic fibrosis (CF) and COPD, affect millions of people worldwide. However, current diagnostics don’t necessarily...
Seeing Asthma Differently with the 4Dx Scanner. Targeting specific airways instead of overall airflow
Cleveland Clinic Lerner Research Institute was recently awarded funding from the National Institutes of Health (NIH) to purchase a leading-edge preclinical scanner from 4Dx Limited, a Melbourne-based medical technology company, to investigate the causes and treatment of asthma. Cleveland Clinic becomes only the second institution...
4Dx 2017 Retail Investment Round Closing 28 June
4Dx Limited is pleased to announce that our retail fundraising offer, under our Offer Information Statement disclosure document dated 20 October 2017, will be closing on 28 June 2018, fully subscribed. We are currently taking oversubscriptions and the offer remains open to all Australian residents. Please...
Australian National Imaging Facility (NIF) to Establish 4Dx Research Eco-system in Adelaide
4Dx is pleased to announce that following increased Federal Government budget to the National Imaging Facility (NIF), a 4Dx technology translational research eco-system will be established in Adelaide. Operating out of the SAHMRI LARIF Node of NIF location, collaborators will be able use 4Dx technology on mice, sheep,...
2018 American Thoracic Society (ATS) Conference
4Dx attended this year’s American Thoracic Society (ATS) Conference held May 18-23 in San Diego. ATS represented a unique opportunity to launch 4Dx Group brands to industry and communicate our unique offering to Physicians and Researchers. It also facilitated dialogue with the pharmaceutical industry. Our...
Second National Institutes of Health Grant to 4Dx
A second major USA hospital has received a grant award of US $600,000 from the United States National Institutes of Health for the purchase of a 4Dx preclinical lung scanner. Scheduled for delivery later this year, the second scanner will greatly increase the profile of...
Medgaget Interview: 4Dx Uses Algorithms to Better Visualize Lung Function
Chronic obstructive pulmonary disease affects millions of people in the United States. The main method of diagnosis is the pulmonary function tests (PFTs), in which a patient breathes into a machine that measures pulmonary parameters. The disadvantage, however, is that pulmonary function tests take an...
Series B capital round update
Melbourne, Australia, March 2018: 4Dx Limited is pleased to announce that the $5M Series B capital round is fully subscribed. However, based on continued strong interest in the round, the Board has agreed to extend the offer period for a limited time to accept oversubscriptions....
4Dx FDA Regulatory Update
4Dx attended a 510(k) pre-submission meeting with the FDA in Silver Spring, Maryland, on March 15th, well ahead of the planned date of April 26th. The meeting was very cordial and productive, providing 4Dx with valuable feedback regarding our planned pipeline of regulatory clearances. Cleared...
4Dx Lung Technology’s Equine Application Featured
From The Sydney Morning Herald DECEMBER 31 2017: 4Dx’s dimensional imaging technology largely focuses on early detection and monitoring of lung diseases in humans, such as cystic fibrosis. Now, 4Dx is keen to adapt the technology to racehorses and has engaged leading Australian equine veterinary surgeon...
4Dx participates in Great Strides run for cystic Fibrosis
Last Sunday, the 4Dx team participated in the Melbourne Great Strides 8K to raise money and awareness for Cystic Fibrosis Community Care (CFCC). CFCC is a non-profit organization working to support those living with and affected by cystic fibrosis. 4Dx’s technology aims to help with...
4Dx assigned Intellectual Property relating to core 4Dx technology
4Dx is pleased to announce that key intellectual property relating to the Company’s 4DxV technology has been assigned from Monash University to 4Dx Limited. The intellectual property (IP) was developed by 4Dx Chairman and CEO, Andreas Fouras, while working at Monash University and was previously...
FDA Update & Future Plans
Earlier this year, 4Dx delivered a 510(k) submission to the FDA for clearance of its 4DxV technology in the radiotherapy setting. Following that submission, the FDA responded with a Request for Additional Information. To clarify the FDA’s request, 4Dx sought and gained a meeting with...
4Dx Preclinical Scanner Project to Rapidly Manufacture 2 Preclinical Scanner Units for Delivery in Major US Hospitals
Melbourne, Australia, 19 April 2017: 4Dx Group “4Dx”, Hydrix Pty Ltd “Hydrix”, and Monash University are collaborating “4Dx Pre-Clinical Scanner Project consortium” to rapidly manufacture two pre-clinical scanners for delivery to two major American medical research hospitals by the end of the year. A further...
4Dx visits London, participates in House of Lords event
4Dx is pleased to inform you that our Chairman and CEO, Andreas Fouras, will be lead speaker at a lunchtime debate at the All Party Parliamentary Engineering Group ‘APPEG’ in the House of Lords, London on Tuesday 21st March. The debate series represents a plank of the...
4Dx TO PUBLICLY ANNOUNCE PRELIMINARY CLINICAL TRIAL DATA AT PRESTIGIOUS WORLD LUNG IMAGING EVENT
Melbourne, Australia, 20 February, 2017: Dr. Andreas Fouras, founder and CEO of medical technology company 4Dx Limited, will present preliminary clinical data at the prestigious World Lung Imaging Workshop on the 2nd of March at the University of Pennsylvania. The software technology developed by 4Dx...
NEW STAFF APPOINTMENT: KAREN SIU, PhD- Programme Manager- Medical Device Development
Dr Karen Siu obtained her PhD from Monash University in 2003 in X-ray Physics. Her postdoctoral work as an Australian Synchrotron Research Program Fellow allowed her to explore the applications of synchrotrons, or highly intense x-ray sources, to biomedical research studying cancers of the brain...
4Dx To Close Series A Capital Raise
Melbourne, Australia, November 23, 2016: 4Dx Limited is pleased to announce that, due to an overwhelming response, as of 5pm, Friday, 9th December, 2016, the company’s $4m Series A capital round will be officially closed. It is anticipated that the round will close oversubscribed. 4Dx...
A BREATH OF FRESH AIR FOR MEDICAL IMAGE TECHNOLOGY
4Dx was featured in an article in Australias national daily newspaper, The Australian today. Andreas Fouras, Founder and CEO of 4Dx is interviewed and the article discusses the new software for imaging lung function devised by 4Dx. A BREATH OF FRESH AIR FOR MEDICAL IMAGE...
Appointment of General Manager – Notting Hill Devices
4Dx is excited to announce that Paul Cooke will be taking on the role of General Manager of 4Dx’s specialist hardware subsidiary, Notting Hill Devices. As Paul moves into this role, he will be stepping aside from his role as Non-Executive Director, effective 1st September....
Monash license agreement changes
A number of positive changes have been made to the key licence agreement with Monash University (which grants 4Dx rights to commercialise this technology in exchange for royalty payments). Most notable among these changes is that the funding threshold for assignment of patents has been...
Andreas Fouras, CEO of 4Dx, says backing bright people is a bright idea
Andreas Fouras, Founder and CEO of 4Dx, spoke with Nature Index on the recent call from the National Health and Medical Research Council (NHMRC) for public consultation on the structural review of their grant program. Following criticism that current funding models are failing to support researchers across all stages of their careers, the...
4Dx retail round closes with full subscription
We are pleased to announce that our recent retail offer of shares is now fully subscribed after successfully raising AU$500,000. It is very encouraging to gain backing so enthusiastically from retail investors committed to seeing our technology come to market as fast as possible. These funds take...
AuntMinnie.com interview 4Dx on their advanced visualization tool being used for imaging lung disease
4Dx was interviewed by AuntMinnie.com, an influential community site for radiologists and related professionals in the medical imaging industry. In the article “Advanced visualization tool assesses lung disease”, Eric Barnes interviewed the 4Dx team on the new technique they have developed that combines fluoroscopy and...
4Dx’s CEO talks to the Australian Financial Review about how our culture is stifling innovation
The AFR cover insights from last weeks meeting of 400 of the top people in the innovation sector, where Andreas Fouras, CEO of 4Dx, highlighted one of the biggest problems Australia faces as it seeks to become high tech nation. Contrary to the risk taking the government would...
Yahoo! Finance announces 4Dx as one of five promising new technologies in the fight against lung disease
Yahoo! Finance (via CEOCFO Magazine) has announced 4Dx as one of five innovative new approaches for diagnosis and treatment of lung disease that has the potential to reduce the human and financial toll. Click here to read the full article.
WATCH: 4Dx make world-first breakthrough in lung disease treatment
Andreas Fouras, CEO of 4Dx, talks to Matthew Sadler from Network Ten News about his vision of making a life-changing contribution to global healthcare, and his confidence in this opportunity to build a multi-billion dollar business. Click here to watch the full coverage.
4Dx’s Andreas Fouras speaks alongside Australia’s leading academics and experts at the AFR Innovation Summit 2016
Andreas Fouras, CEO of 4Dx, yesterday joined some of Australias leading scientists and academics at The Australian Financial Reviews Innovation Summit to discuss Australia’s need to change its attitude toward entrepreneurial failure to protect the economy from missing out on the benefits created by risk takers. Dr...
WINTER 2016 NEWSLETTER
4Dx has had a very busy and exciting time over the past 3 months establishing new relationships with several key stakeholder groups. Please click here to access the Winter 2016 edition of the 4Dx newsletter for a full update on our most recent milestones.
4Dx Research Breakthrough: Changing the Face of Diagnostic Imaging
The results of a new pre-clinical study, show that 4Dx’s breakthrough four-dimensional lung diagnostic platform has the ability to better measure the progression and severity of cystic fibrosis (CF) like lung disease – something that is critically lacking in today’s care of patients with lung...
4Dx spoke with StartUp Daily about the future of 4Dx in a billion dollar market
Andreas Fouras, Founder and CEO of 4Dx, spoke with StartUp Daily about the strong need for better diagnostics technology that is cost efficient, more convenient and safer for patients to use. Andreas shared 4Dx’s plan over the next 12 months to take the company public and commence...
Andreas spoke with Anthill Magazine about his move to the U.S and the future of 4Dx
Anthill Magazine caught up with Andreas Fouras, 4Dx Founder and CEO, on his recent move to the U.S to continue to develop partnerships with world leading hospitals, in support of the current capital raise here in Australia. To read the full article click here.
Andreas Fouras, Founder and CEO of 4Dx, is featured in Monash Universities Alumni Newsletter
4Dx Founder and CEO, Andreas Fouras, has been featured in this months Monash Alumni newsletter. As a former Professor at Monash University, the article follows Fouras leap of faith from the laboratory in favour of a more entrepreneurial role as the CEO of 4Dx To read the full...
4Dx’s Executive Director, Steve Peuschel, talks 4Dx and golf with the AFR
Steve Peuchel, 4Dx Executive Director, was featured this weekend in the AFR Life and Leisure magazine. Steve is a key driver of 4Dx’s unique and ground-breaking healthcare technology, and shares his personal story and passions that have motivated his role in potentially improving millions of lives off those...
4Dx attends AusBio events in Singapore and Hong Kong
This week 4Dx will take part in the spotlight presentations to international investors as part of the AusBiotech Global Investment Event Series, with events taking place in Asia, the US and Australia. Through a professional business-matching program 4Dx will connect with life science investors from across the globe...
AFR positions 4Dx as a prime example of successfully commercialised Aussie research
4Dx was again featured in the AFR as a prime example of the successful commercialisation of research from Australian universities. Monash Universities early support for 4Dx’s research has seen that journey from discovery. Professor Ian Smith is Vice-Provost of Research at Monash University has commended Andreas’ entrepreneurial streak in...
Andreas Fouras talks to SBS Radio about how he developed 4Dx’s breakthrough technology
Andreas Fouras, Founder and Executive Chairman of 4Dx talks about his journey to take his ground-breaking lung imaging technology from the lab into the clinic. Andreas shares his drive to provide a technology that gives doctors the best possible information when diagnosing and treating lung...
Andreas talks to Start Up Smart about his pursuit to commercialise 4Dx
Andreas talks to Dinushi Dias from Start Up Smart about his vision of making a life-changing contribution to global healthcare and his confidence in this opportunity to build a multi-billion dollar business. After travelling the world listening to and taking on feedback from health professionals and investors, Fouras...
Andreas Fouras Presents 4dx to Investors at the ASX in Sydney and Melbourne
4Dx took part in a unique opportunity to present to, meet and network with high net worth, private and professional investors to create strategic long-term relationships. Andreas Fouras, Founder and Executive Chairman of 4Dx thought the event be a great success to unlocking future relationships that...
Minister for Small Business, Innovation and Trade and Local Member for Oakleigh visit 4Dx
The Minister for Small Business, Innovation and Trade, Mr Philip Dalidakis and local State Member for Oakleigh Steve Dimopolous MP, had the opportunity to experience 4Dx’s groundbreaking four-dimensional lung imaging technology, when he visited us on Friday, 18th March 2016. Andreas Fouras, Founder and Executive...
Minds of Malady features 4Dx for our innovation and potential to save lives
Morten Bjørklund takes a look at our new approach to lung imaging to map lung function in 4-dimensions. Click here to learn more.
SBS World News features 4Dx as they set their sights on the US
Our 4Dx lung imaging technology was showcased on SBS World News, with Sarah Abo, on Wednesday the 3rd of March 2016 The news feature demonstrated how 4Dx is advancing beyond an x-ray image, with first of its kind software that captures a 4D animation of...
Step inside the human lung
Over the past couple of months our team have been lucky enough to experience Monash University’s Immersive Visualisation Platform (MVIP) – otherwise known as the CAVE2. With a cylindrical 8-meter diameter video wall, the Cave takes ‘immersive’ to a whole new level – providing a...
Andreas Fouras honoured in the Lawrence Creative Prize
Andreas Fouras, Monash University Professor of Engineering and Founder of Melbourne-based early stage medtech company, 4Dx, has been honoured as a finalist inThe Centenary Institute’s Lawrence Creative Prize – an award that recognises young Australian scientists. Held last night in Sydney, Andreas was recognised by...
4Dx appoints clinical advisory board
Melbourne based medical technology start-up 4Dx has engaged the services of a Clinical Advisory Board to review and make clinical recommendations on the company’s four-dimensional lung imaging technology. According to the company, the four-dimensional X-ray imaging technology (4DxV) provides a state-of-the-art, non-invasive way of understanding...
World COPD Day
World COPD Day is an annual event to improve the awareness and care of chronic obstructive pulmonary disease around the world, organised by the Global Initiative for Chronic Obstructive Lung Disease. Chronic Obstructive Pulmonary Disease is a type of obstructive lung disease characterised by chronic,...
Our technology features on Australian news segments
The real world context of our 4D lung imaging technology was showcased on the Saturday 13th September 2014 editions of Australian 7 National News. Our flagship 4-dimensonal X-ray imaging technique, maps the breathing lung, providing measurements of lung function at low radiation dose, highlighting the potential...
Andreas discusses our imaging technology on Radio National
Andreas discusses our flagship 4D lung imaging technology with renowned ABC science journalist Robyn Williams, on today’s broadcast of Radio National‘s The Science Show. In the interview, Andreas draws attention to how our technology’s new approach is different to what is available in the clinic...
4Dx tests Andor Tech’s Zyla sCMOS HF camera
We were recently approached by Andor Technology PLC to test their new Zyla sCMOS HF camera ahead of release. Andor Technology is a developer and manufacturer of high performance light measuring solutions (scientific digital cameras). Andor became a subsidiary of Oxford Instruments after it was...
Research ventilator development update
As part of our ongoing research and development activities, we have the need for robust, precise ventilation strategies — ideally interchangeable between physiological profiles and standard pulmonary function test manoeuvres. Although many off the shelf research ventilators are available, our extensive and varied technical needs...
Steve wins Stephen Wilkins Medal for technology
Congratulations to Steve, who today was presented with the inaugural Australian Synchrotron Stephen Wilkins Thesis Medal (2013) at the 2013 Australian Synchrotron User Meeting. The Australian Synchrotron Thesis Medal, now named in honour of the late Dr Stephen Wilkins, is awarded to annually to the...
Andreas receives Excellence Award for technology
Congratulations Andreas, who tonight was awarded the 2013 Monash University’s Vice-Chancellor’s Award for Excellence in Research by an Early Career Researcher. This exclusive award recognises Andreas’s development of the 4D X-ray lung imaging technology to improve human health. The ceremony was held in Flemington, and...
4Dx opens Melbourne office
With the beginning of the new financial year, we are pleased to announce that after successfully raising $1 million in seed capital, we have opened our Melbourne office and commenced operations. As a medtech startup, we plan to commercialise our 4D lung imaging software technology,...
Commercial use licence of our lung imaging technology secured
We have successfully completed negotiations with Monash University for exclusive commercial use of our 4-dimensional imaging technology. The agreement covers multiple separate patents that apply across all current major target geographies. My research team at LDI developed the technology which directly images lung function in...
Andreas honoured with Australian Leadership Award
Congratulations Andreas, who tonight was awarded with a 2013 Australian Davos Connection (ADC) Australian Leadership Award. The evening was highlighted by an address given by The Hon Julia Gillard MP, Prime Minister of Australia. Andreas, joins 18 other recipients of the award this year, who...
Medical collaboration featured in The Australian
Edwin Jesudason, Associate Professor of Paediatric Surgery from the University of Liverpool, has been a great source of inspiration to our team through his invaluable medical expertise and insightful views of interdisciplinary research (from a clinician’s perspective). Refreshingly, he shares the same passion as us...
Tribute to X-ray imaging pioneer Steve Wilkins
It is with great sadness that we remember Australian X-ray physicist Dr Stephen William Wilkins, who suddenly passed away in Melbourne on the 25th of March 2013. Steve’s major contributions to the areas of X-ray methods and X-ray instrumentation paved the way for widespread implementation...
